Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
44.59B
Market cap44.59B
Price-Earnings ratio
144.32
Price-Earnings ratio144.32
Dividend yield
Dividend yield
Average volume
1.59M
Average volume1.59M
High today
$345.90
High today$345.90
Low today
$335.08
Low today$335.08
Open price
$336.58
Open price$336.58
Volume
1.36M
Volume1.36M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 44.59B, Alnylam Pharmaceuticals(ALNY) trades at $336.19. The stock has a price-to-earnings ratio of 144.32.

As of 2026-02-22, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $335.08 and $345.90. The current price stands at $336.19, placing the stock +0.3% above today's low and -2.8% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 1.36M, compared to an average daily volume of 1.59M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 3d
Assessing Alnylam Pharmaceuticals Valuation After First Profitable Year And Rapid Revenue Growth

Alnylam Pharmaceuticals (ALNY) is back in focus after its latest earnings report, where revenue for 2025 reached US$3.71 billion and the company reported full-y...

Assessing Alnylam Pharmaceuticals Valuation After First Profitable Year And Rapid Revenue Growth
Simply Wall St 5d
Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise. The company introduces a new RNAi manufac...

Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise
TipRanks 5d
Alnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating

Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst on February 13. Analyst Whitney Ijem from Canaccord Genuity maintained a B...

Analyst ratings

76%

of 29 ratings
Buy
75.9%
Hold
24.1%
Sell
0%

More ALNY News

TipRanks 5d
Alnylam price target raised to $429 from $415 at Canaccord

Canaccord raised the firm’s price target on Alnylam (ALNY) to $429 from $415 and keeps a Buy rating on the shares. The firm updated its model following Q4 resul...

TipRanks 6d
Alnylam upgraded to Buy from Hold at Freedom Capital

Freedom Capital upgraded Alnylam (ALNY) to Buy from Hold with a price target of $410, down from $470. The company’s Amvuttra continues to post “exceptional” rev...

Simply Wall St 7d
Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' Narrative?

In February 2026, Alnylam Pharmaceuticals reported its fourth-quarter and full-year 2025 results, showing revenue rising to US$1.10 billion for the quarter and...

Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' Narrative?

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.